Principal Investigator:
Samie R. Jaffrey, Professor of Pharmacology
Background & Unmet Need
- RNA aptamers are small RNAs capable of folding into complex structures, allowing them to bind to metabolites, proteins, or other molecules and thereby regulate cellular functions
- Various aptamers have been successfully selected against different targets and show promise as a diagnostic, prognostic and therapeutic
- Efficient RNA circularization has led to the development of aptamers resistant to exonucleases, making them highly stable and abundant within cells
- However, their constitutive binding can lead to toxicity
- Allosteric control by theophylline and tetracycline binding aptamers is possible but leads to unwanted biological effects, such as increased cyclic AMP and altered microbiomes and antibiotic resistance
- Unmet Need: Reliable method to control the activity of RNA aptamers in a reversible and tunable manner with minimal off-target effects
Technology Overview
- The Technology: A platform for generating acyclovir-controlled RNA nanodevices that can be used for controlling cell physiology
- The nanodevice incorporates two aptamers: the first aptamer (input) exhibits a conformational change upon binding acyclovir, which stabilizes the second aptamer (output) in a folded conformation that binds to an effector or performs an effector function
- PoC Data: Engineered an RNA nanodevice that successfully demonstrated acyclovir-dependent control of Broccoli, a fluorogenic aptamer
- Engineered an RNA nanodevice containing an iron response element (IRE), an aptamer that binds to the major undruggable iron-regulatory proteins (IRPs), enabling tunable repression of free iron levels and thus the inhibition of ferroptosis
- Compared to samples without acyclovir, those with acyclovir exhibited up to a 126% increase in FTH levels and up to a 22% decrease in TfR expression
Technology Applications
- A platform for developing RNA-based therapeutics, particularly for controlling iron homeostasis and preventing ferroptosis
- Integrated into existing gene therapy platforms to enhance the control of gene expression
- As a tool in for studying cellular processes and pathway regulations
Technology Advantages
- Reversible and tunable control of aptamer function through external activators, allows for precise modulation and reset of expression
- Activation by specific, non-toxic small molecules like acyclovir ensures targeted action with minimal side effects
- Applicable to various cellular functions including mRNA cleavage, splicing, and polyadenylation
Resources
Intellectual Property
Patents
- Provisional Application Filed
Cornell Reference
- 11080
Contact Information
For additional information please contact
Jamie Brisbois
Manager, Business Development and Licensing
Phone: (646) 962-7049
Email: jamie.brisbois@cornell.edu